NKTX · Nkarta, Inc.

$2.47 -0.07 (-2.76%) At close · Aug 20

Market Cap

$181.93M

71.62M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul J. Hastings	Chief Executive Officer	$674,384	—	$236,250	$1,711,957	$344,947	$10,500	$2,978,038
Nadir Mahmood	President	$543,250	—	$155,000	$434,646	$252,611	$10,500	$1,396,007
Shawn Rose	M.D., Ph.D. Chief Medical Officer and Head of Research and Development	$316,591	—	—	$709,300	$189,720	$9,162	$1,224,773

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul J. Hastings	Chief Executive Officer	$648,446	—	$510,850	$2,494,818	$320,981	$10,350	$3,985,445
Nadir Mahmood	President	$226,354	—	—	$3,001,680	$101,281	$6,801	$3,336,117
David Shook	Chief Medical Officer, Head of Research and Development	$489,507	—	$500,975	$723,122	$176,229	$10,350	$1,900,182

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul J. Hastings	Chief Executive Officer	$623,506	—	$359,265	$1,640,267	$301,777	$9,900	$2,934,715
David Shook	Chief Medical Officer, Head of Research and Development	$459,800	—	$208,875	$669,625	$161,850	$9,900	$1,510,050
Alyssa Levin	Chief Financial and Business Officer	$225,000	$20,000	—	$749,558	$117,607	$174,793	$1,286,958
Nadir Mahmood	President	$283,077	—	$208,875	$318,293	—	$9,900	$820,145

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul J. Hastings	President and Chief Executive Officer	$599,525	—	$747,541	$3,058,795	$329,739	$9,150	$4,744,750

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul J. Hastings	President and Chief Executive Officer	$576,466	—	—	$5,872,808	$317,057	$8,700	$6,775,031
Dr. Kanya Rajangam	Chief Medical Officer	$446,200	—	—	$1,957,603	$178,480	$8,700	$2,590,983
Dr. Nadir	Mahmood Chief Financial and Business Officer	$416,100	—	—	$1,957,603	$166,440	$8,700	$2,548,843

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Matthew	Plunkett	$299,554	—	—	$3,251,053	—	$321,159	$3,871,766
Dr. Alicia Hager	Chief Legal Officer and Corporate Secretary	$72,386	—	—	$3,181,814	$23,400	$2,366	$3,279,966
Paul J. Hastings	President and Chief Executive Officer	$559,697	—	—	$2,360,345	$251,854	$8,550	$3,180,446
Dr. Nadir	Mahmood Chief Financial and Business Officer	$348,615	—	—	$1,895,203	$122,011	$8,550	$2,374,379
Dr. Kanya Rajangam	Chief Medical Officer	$435,024	—	—	$823,322	$151,410	$8,550	$1,418,306

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul J. Hastings	President and Chief Executive Officer	$543,375	—	—	$2,086,077	$232,293	$8,400	$2,870,145
Former Chief	Financial Officer	$342,876	—	—	$589,147	$116,375	$8,400	$1,056,798

Executive changes

Person	Role	Change	Effective	Filed
Shawn Rose, M.D. Ph.D.	Chief Medical Officer and Head of Research and Development	Appointed	2025-06-23	2025-06-06
David Shook, M.D.	Chief Medical Officer and Head of Research & Development	Resigned	2025-06-06	2025-06-06
Nadir Mahmood	principal accounting officer	Appointed	2025-03-31	2025-03-26
Nadir Mahmood	principal financial officer	Appointed	2025-03-31	2025-03-26
Alyssa Levin	Chief Financial and Business Officer	Terminated	2025-03-31	2025-03-26
Nadir Mahmood	President	Appointed	2024-07-29	2024-07-16
Alyssa Levin	Chief Financial and Business Officer	Appointed	2023-07-01	2023-07-05
Dr. Nadir Mahmood	Chief Financial and Business Officer	Resigned	2023-06-30	2023-03-30
David R. Shook	Vice President, Clinical Development	Appointed	—	2022-05-16
Kanya Rajangam	Chief Medical Officer	Resigned	2022-06-05	2022-05-16
Angela Thedinga	independent Class I director	Appointed	2022-03-28	2022-03-29
Nadir Mahmood	Chief Financial and Business Officer	Appointed	2020-10-02	2020-10-05
Matthew Plunkett	Chief Financial Officer	Resigned	2020-10-02	2020-10-05

Key facts CIK 1787400 CUSIP 65487U108 13F (30d) 124 filings 124 filers Visit website Investor relations